Latest news

News archive

Job Opening – Process Chemist

10 February, 2021

We are currently looking for a Process Chemist who likes to solve problems and develop optimised ways of working. You will work closely with our manufacturing unit, but it is R&D that is hosting this position. Formulation and chemical modification are key words! Read more about the job and how to apply here: Job advertisement Process Chemist at Nanologica Last application date: Feb 25, 2021.

CEO Andreas Bhagwani comments on the test material from large-scale production

26 January, 2021

Intervju med vd Andreas Bhagwani av Erik Penser Banks Klas Palin 17 dec 2020

18 December, 2020

Penser Access inleder bevakning av Nanologica

18 December, 2020

Penser Access inleder bevakning av Nanologica genom Klas Palins försorg. Idag släpptes en initierande uppdragsanalys som finns att läsa via Penser Access. Länk till analysen

DDL 2020 – Drug Delivery to the Lungs Conference

9 December, 2020

Nanologica is attending the Drug Delivery to the Lungs conference (DDL) during Dec 9-11. The DDL is the premier conference and industry exhibition which is dedicated to pulmonary and nasal drug delivery. The focus is on providing a forum to present t recent developments in the field of inhalation therapy. Representing Nanologica is Prof. Adam Feiler, CTO.

Prof. Adam Feiler Commenting on Empty Porous Silica Particles for the Treatment of ALS

26 November, 2020

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.